Loading...
Loading...
Top Upgrades
- BMO Capital upgraded Polaris Industries Inc. PII from Market Perform to Outperform. Polaris shares rose 4.6 percent to $89.89 in pre-market trading.
- Analysts at Bernstein upgraded Kroger Co KR from Market Perform to Outperform. Kroger rose 1.5 percent to $24.42 in pre-market trading.
- Analysts at Canaccord Genuity upgraded Just Energy Group Inc JE from Hold to Speculative Buy. Just Energy shares rose 1.3 percent to $3.25 in pre-market trading.
- Guggenheim upgraded Tripadvisor Inc TRIP from Sell to Neutral. TripAdvisor shares rose 1.9 percent to $45.80 in pre-market trading.
- Bank of America upgraded Deckers Outdoor Corp DECK from Neutral to Buy. Deckers Outdoor shares rose 0.1 percent to close at $142.74 on Monday.
- Zelman upgraded Stanley Black & Decker, Inc. SWK from Hold to Buy. Stanley Black & Decker rose 0.2 percent to close at $135.12 on Monday.
- Credit Suisse upgraded Apollo Global Management LLC APO from Neutral to Outperform. Apollo Global shares fell 0.6 percent to close at $32.13 on Monday.
- Analysts at UBS upgraded S&P Global Inc SPGI from Neutral to Buy. S&P Global shares fell 0.5 percent to close at $211.83 on Monday.
- Raymond James upgraded Amneal Pharmaceuticals Inc AMRX from Market Perform to Strong Buy. Amneal Pharmaceuticals rose 5.1 percent to $8.68 in pre-market trading.
Â
Top Downgrades
- Desjardins downgraded Cae Inc CAE from Buy to Hold. CAE shares fell 0.4 percent to $26.57 in pre-market trading.
- RBC Capital downgraded Gran Tierra Energy Inc GTE from Top Pick to Outperform. Gran Tierra Energy shares closed at $2.14 on Monday.
- Raymond James downgraded Ocular Therapeutix Inc OCUL from Strong Buy to Outperform. Ocular Therapeutix shares fell 15.7 percent to $2.84 in pre-market trading.
- Credit Suisse downgraded The Carlyle Group LP CG from Outperform to Neutral. Carlyle shares fell 0.8 percent to close at $20.76 on Monday.
- Credit Suisse downgraded KKR & Co Inc KKR from Outperform to Neutral. KKR shares fell 0.7 percent to close at $24.50 on Monday.
- UBS downgraded Tremont Mortgage Trust TRMT from Buy to Neutral. Tremont Mortgage Trust rose 0.4 percent to close at $5.17 on Monday.
Â
Top Initiations
- Analysts at Credit Suisse initiated coverage on Amgen, Inc. AMGN with an Outperform rating. The price target for Amgen is set to $208. Amgen shares closed at $168.39 on Monday.
- Consumer Edge Research initiated coverage on Uber Technologies Inc UBER with an Equal-Weight rating. Uber shares closed at $41.59 on Monday.
- Deutsche Bank initiated coverage on Target Hospitality Corp TH with a Buy rating. The price target for Target Hospitality is set to $14. Target Hospitality shares closed at $10.83 on Monday.
- Analysts at Credit Suisse initiated coverage on Incyte Corporation INCY with a Neutral rating. The price target for Incyte is set to $75. Incyte shares closed at $76.83 on Monday.
- Canaccord Genuity initiated coverage on X4 Pharmaceuticals Inc XFOR with a Buy rating. The price target for X4 Pharmaceuticals is set to $27. X4 Pharmaceuticals closed at $16.96 on Monday.
- H.C. Wainwright initiated coverage on Aeglea Bio Therapeutics Inc AGRX with a Buy rating. The price target for Aeglea Bio Therapeutics is set to $20. Aeglea Bio Therapeutics shares closed at $6.50 on Monday.
- Analysts at DA Davidson initiated coverage on Hillenbrand, Inc. HI with a Neutral rating. The price target for Hillenbrand is set to $43. Hillenbrand closed at $38.96 on Monday.
- Empire Asset Management initiated coverage on Evolus Inc EOLS with a Sell rating. The price target for Evolus is set to $6. Evolus closed at $17.38 on Monday.
- Credit Suisse initiated coverage on Biogen Inc BIIB with an Underperform rating. The price target for Biogen is set to $198. Biogen shares closed at $230.76 on Monday.
- Analysts at Credit Suisse initiated coverage on Vertex Pharmaceuticals Incorporated VRTX with an Outperform rating. The price target for Vertex Pharmaceuticals is set to $209. Vertex Pharmaceuticals shares closed at $165.73 on Monday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in